Manulife secondaries business to target Asia
Manulife Investment Management will target Asia with a newly launched private markets secondary business.
“Given Manulife Investment Management’s long-standing presence in the region, we expect the Asian secondaries business to become a core component of the overall Manulife secondaries business in time,”...
More on LPs
Latest News
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
PE investors agree $5.7b 51job take-private
A consortium led by DCP Capital Partners has finalized terms for a $5.7 billion privatization of US-listed Chinese online recruitment platform 51job.
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.